Andrographolide ameliorates neuroinflammation in APP/PS1 transgenic mice

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no current disease-modifying treatments.
• Neuroinflammation is increasingly recognized as a key factor in AD pathogenesis.
• Andrographolide (Andro), derived from Andrographis paniculata, shows neuroprotective potential but its effects on AD-related neuroinflammation are unexplored.

Purpose of the Study:

• To investigate the therapeutic effects of Andrographolide (Andro) on amyloid-β (Aβ) pathology and neuroinflammation in a mouse model of Alzheimer's disease.
• To explore the molecular mechanisms underlying Andro's effects on neuroinflammation.

Main Methods:

• Administration of Andrographolide (Andro) to APP/PS1 transgenic mice, a model for Alzheimer's disease.
• Assessment of cognitive function, amyloid-β deposition, and microglial activation.
• Transcriptome sequencing and quantitative real-time PCR (qRT-PCR) to analyze gene expression changes.

Main Results:

• Andro treatment significantly improved cognitive impairments in APP/PS1 mice.
• Reduced amyloid-β deposition and inhibited microglial activation were observed.
• Andro decreased the secretion of pro-inflammatory factors and downregulated key inflammatory genes including Itgax, TLR2, CD14, CCL3, CCL4, TLR1, and C3ar1.

Conclusions:

• Andrographolide (Andro) demonstrates significant therapeutic potential for Alzheimer's disease.
• Andro may exert its beneficial effects by modulating neuroinflammation and reducing amyloid-β pathology.
• Further research into Andro as a potential drug for AD is warranted.